| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 136, Issue 7 2483-2485, Copyright © 1986 by American Association of Immunologists
ARTICLES |
R Neta, S Douches and JJ Oppenheim
Pretreatment with recombinant interleukin 1 (IL 1) protects mice in a dose-dependent manner from lethal effects of ionizing radiation. Two thousand units of IL 1, given i.p. 20 hr before irradiation, protect 88% of C57B1/6 mice from an LD100/17 radiation dose (dose of radiation that kills 100% mice in 17 days), and 1000 U of IL 1 protect 100% of DBA/1 mice from an LD50/30 dose. This finding provides the first evidence that a cytokine, IL 1, which acts as a differentiation- and maturation-inducing agent for a variety of cells, also can serve as a signal that initiates radioprotective events in vivo. Because many of the exogenous immunomodulators that have been shown to be radioprotective also induce endogenous IL 1 production, our observation suggests that IL 1 may mediate their radioprotective effects.
This article has been cited by other articles:
|
|
 |
|
  X. Song, Y. Krelin, T. Dvorkin, O. Bjorkdahl, S. Segal, C. A. Dinarello, E. Voronov, and R. N. Apte CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1{beta}-Secreting Cells J. Immunol., December 15, 2005; 175(12): 8200 - 8208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Riehl, R. D. Newberry, R. G. Lorenz, and W. F. Stenson TNFR1 mediates the radioprotective effects of lipopolysaccharide in the mouse intestine Am J Physiol Gastrointest Liver Physiol, January 1, 2004; 286(1): G166 - G173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Panoskaltsis-Mortari, P. A. Taylor, J. S. Rubin, A. Uren, L. A. Welniak, W. J. Murphy, C. L. Farrell, D. L. Lacey, and B. R. Blazar Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury Blood, December 15, 2000; 96(13): 4350 - 4356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Veltri and J. W. Smith II Interleukin 1 Trials in Cancer Patients: A Review of the Toxicity, Antitumor and Hematopoietic Effects Oncologist, August 1, 1996; 1(4): 190 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Veltri and J. Smith 2nd Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects Stem Cells, March 1, 1996; 14(2): 164 - 176. [Abstract]
|
|
|
|
 |
|
 J. W. Smith, D. L. Longo, W. G. Alvord, J. E. Janik, W. H. Sharfman, B. L. Gause, B. D. Curti, S. P. Creekmore, J. T. Holmlund, R. G. Fenton, et al. The Effects of Treatment with Interleukin-1{alpha} on Platelet Recovery after High-Dose Carboplatin N. Engl. J. Med., March 18, 1993; 328(11): 756 - 761. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Wong and D. Goeddel Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism Science, November 11, 1988; 242(4880): 941 - 944. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
